Clinical Research Directory
Browse clinical research sites, groups, and studies.
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
Sponsor: AstraZeneca
Summary
ANCHOR is a prospective, phase IV, interventional, single-arm, open-label study of 1,500 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonide inhalation aerosol as rescue therapy.
Official title: ANCHOR - Assessment of Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
Key Details
Gender
All
Age Range
18 Years - 130 Years
Study Type
INTERVENTIONAL
Enrollment
1511
Start Date
2024-05-10
Completion Date
2027-03-31
Last Updated
2026-04-06
Healthy Volunteers
No
Conditions
Interventions
Albuterol and budesonide inhalation aerosol
Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period.
Locations (11)
Research Site
North Hollywood, California, United States
Research Site
Walnut Creek, California, United States
Research Site
Louisville, Kentucky, United States
Research Site
Boston, Massachusetts, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Flint, Michigan, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Asheville, North Carolina, United States
Research Site
Greenville, North Carolina, United States
Research Site
DuBois, Pennsylvania, United States
Research Site
Austin, Texas, United States